Please enable Javascript to use all features and improve your user experience.
EHC 2024
Programme
Posters
Search
EN
Posters on the topic "Migraine"
Back
P071
ePoster
Contemporary prospective understanding of migraine real-world evidence (CAPTURE): baseline clinical characteristics
Laurent Delahaye (Toronto, CA)
P072
ePoster
Difference in sensitization mechanism across low-frequency episodic, high-frequency episodic, and chronic migraine
Stefano Di Antonio (Aalborg, DK)
P073
ePoster
Comorbidity rates in a large cohort of patients with migraine – a real-world data analysis
Matanya Tirosh (Herzliya, IL)
Danna Davidovici (Herzliya, IL)
P074
ePoster
Milk and plasma pharmacokinetics of single-dose atogepant in healthy lactating women
Ramesh Boinpally (North Chicago, IL, US)
P075
ePoster
Evidence of visual hyperexcitability during and outside of migraine attacks – a reform functional MRI study
Rune Häckert Christensen (Glostrup, DK)
P076
ePoster
Impact of Atogepant on daily functioning in patients with episodic migraine and chronic migraine: Activity Impairment in Migraine-Diary (AIM-D) Item-Level analysis
Richard B. Lipton (Bronx, NY, US)
P077
ePoster
The impact of the migraine treatment Botulinum toxin on inflammatory and pain responses: insights from an animal model
Philip Victor Reducha (Copenhagen, DK)
P078
ePoster
Results from the 2
nd
Italian interim analysis of the PEARL study: concomitant acute medication use Over 12 months of Fremanezumab treatment
Gabriella Egeo (Rome, IT)
P079
ePoster
Differences in cortical activity in interictal, ictal, and chronic migraine
Marco Lisicki (Madrid, ES; Córdoba, AR)
P080
ePoster
Decreased intracortical inhibition in patients with hemiplegic migraine – a transcranial magnetic stimulation (TMS) study
Genevieve Demarquay (Bron, FR)
P081
ePoster
Long-term (72-week) improvement in headache frequency, severity, and burden following early headache reduction with eptinezumab for migraine prevention
Cristina Tassorelli (Pavia, IT)
P082
ePoster
Impact of Atogepant on achieving complete improvement as early as week 1 based on the Activity impairment in Migraine-Diary (AIM-D) domains: post hoc analysis from the ADVANCE, ELEVATE, and PROGRESS trials
Andreas R. Gantenbein (Bad Zurzach, CH)
P083
ePoster
Predictors of sleep quality in patients with chronic migraine – a clinical study from Taiwan
Yu Ming Chen (Hualien City, TW)
P084
ePoster
Primary senses and migraine – an observational study
Debi Dutta Das (Mohali, IN)
P085
ePoster
Migraine experiences beyond typical symptoms and interventions
Sheharyar Ahmad (Caserta, IT)
P086
ePoster
Headache in mediterranean anemias – a comparative study of Albanian patients
Ereida Rraklli (Tirana, AL)
P087
ePoster
Which combination of comorbidity makes migraine treatment impossible? A graphical approach
Pengfei Zhang (New Brunswick, NJ, US)
P088
ePoster
Which types of headaches in the migraine and tension-type spectrum cannot be diagnosed by ICHD3?
Pengfei Zhang (New Brunswick, NJ, US)
P089
ePoster
Acute Migraine in CADASIL
Shadi Zamanian (Mashhad, IR)
P090
ePoster
Retrospective study in patients with chronic and refractory migraine treated with Eptinezumab
Celia Santillana Avila (Granada, ES)
P091
ePoster
Pattern and adherence to Prophylactic treatment in migraine: a multi-center study in Egypt
Mona Nada (Cairo, EG)
P166
ePoster
Migraine does not rest in the arms of Morpheus – a descriptive analysis of sleep quality
Marcos Polanco Fernández (Santander, ES)
P167
ePoster
French migraine patients ineligible for or resistant to triptans: a primary care real-world study – France-Mig study
Michel Lantéri-Minet (Nice, FR)
P168
ePoster
Long-term sustained response of Atogepant in episodic and chronic migraine: an interim analysis of a phase 3, open-label, 156-week safety extension study
Patricia Pozo-Rosich (Barcelona, ES)
P169
ePoster
Salivary CGRP1/CT ratio and Cytokine profile as potential biomarkers of migraine
Yelena Nersesyan (Peoria, IL, US)
P170
ePoster
Interictal burden before initiating Calcitonin gene-related peptide monoclonal antibody for migraine prevention
Christian Lampl (Linz, AT)
P171
ePoster
Anti-CGRP monoclonal antibodies improve sleep quality in migraine patients – a 1-year, multicenter, longitudinal study
Cinzia Aurilia (Rome, IT)
P172
ePoster
Differences in structural neuroimaging in migraine and healthy controls
Joana Rosell-Mirmi (Barcelona, ES)
P173
ePoster
Switching between triptans: real-life findings from a headache outpatient clinic
Liliana Pereira (Almada, PT)
P174
ePoster
Comparing candesartan and Vitamin E for prophylactic treatment in episodic migraine patients
Annemijn Oosterlee (Leiden, NL)
P175
ePoster
Impact of neck pain with headache among people with migraine, adjusting for headache frequency – Multicountry results from the chronic migraine epidemiology and outcomes – International cross-sectional study
Richard B. Lipton (Bronx, NY, US)
P176
ePoster
Tryptophan metabolism in migraine
Michal Fila (Lodz, PL)
P177
ePoster
All-cause and cause-specific mortality in persons with migraine – a Danish nationwide cohort study
Cecilia Hvitfeldt Fuglsang (Aarhus, DK)
P178
ePoster
Migraine preventive treatment with eptinezumab improved patient-reported outcomes in patients with non-response on frequency of monthly migraine days
Jessica Ailani (Washington, DC, US)
P179
ePoster
Treatment with Zavegepant offers improvements in pain severity over 48-hours when compared with Placebo – post hoc results from a randomized Placebo-controlled trial (BHV3500-301)
Jessica Cirillo (New York, NY, US)
P180
ePoster
Contemporary prospective understanding of migraine real-world evidence (CAPTURE): baseline patient-reported outcomes
Elizabeth Leroux (Montreal, CA)
Laurent Delahaye (Toronto, CA)
P181
ePoster
Long-term safety and discontinuation for rimegepant versus lasmiditan – a matching-adjusted indirect comparison
Aaron Jenkins (Surrey, GB)
P182
ePoster
Chronic migraine and ergots use cause higher serum pentraxin 3 levels and endothelial dysfunction in migraine
Mona Nada (Cairo, EG)
P183
ePoster
Impact of Fremanezumab cessation and reinitiation in migraine management: PEARL study 4th interim analysis
Tomáš Nežádal (Prague, CZ)
P184
ePoster
Physical activity levels analysis in patients with chronic migraine treated with Fremanezumab. Phy-My-Mig Study
Álvaro Sierra Mencia (Valladolid, ES)
P185
ePoster
Migraine prevalence: findings from the Americas' Migraine Observatory Study (AMIGOS)
Marco Lisicki (Córdoba, AR)
P186
ePoster
Changes in acute migraine medications use after initiating or switching to a migraine preventive medication: 12-month findings from the observational TRIUMPH study
Maurice Vincent (Rio de Janeiro, BR)
P187
ePoster
Real-world evidence of adding atogepant to OnabotulinumtoxinA for control of chronic migraine – a retrospective chart review
Aubrey Manack Adams (Irvine, CA, US)
P188
ePoster
Real-world treatment patterns of Galcanezumab and traditional oral migraine preventives: 12-month results from the TRIUMPH study
Maurice Vincent (Rio de Janeiro, BR)
P189
ePoster
Real-world evaluation of Eptinezumab in Italy: effectiveness, tolerability, and safety in high-frequency and chronic migraine at 12 weeks – the EMBRACE study
Cinzia Aurilia (Rome, IT)
P190
ePoster
A cross-sectional analysis evaluating the humanistic and economic burden of migraine with comorbid depression using the national health and wellness survey
Hasan Akcicek (Amsterdam, NL)
P191
ePoster
Lasmiditan for migraine. Experience in a headache center in Barcelona
Afra Irene Gilbert (Barcelona, ES)
P192
ePoster
Integrative analysis of omics markers associated with neuronal damage in migraine
Victor Jose Gallardo López (Barcelona, ES)
P193
ePoster
Exploring the link between inhibitory cognitive control and sensory sensitivity in migraine – a case-control study
Nara Ikumi (Barcelona, ES)
P194
ePoster
Manual therapy as a prophylactic treatment for migraine. A randomized controlled trial
Andreas Amons (Amsterdam, NL)
P195
ePoster
Switching between Ligand and receptor anti-CGRP antibodies in non-responders
Nancy van Veelen (Leiden, NL)
P196
ePoster
Migraine under treatment: Findings from the Americas' Migraine Observatory Study (AMIGOS)
Marco Lisicki (Córdoba, AR)
P197
ePoster
MultiHEAD – work-focused multidisciplinary headache treatment
Oda Vardenær Lunder (Oslo, NO; Trondheim, NO)
P198
ePoster
Migraine epidemiology in Israel – a retrospective database study
Matanya Tirosh (Herzliya, IL)
Danna Davidovici (Herzliya, IL)
P199
ePoster
Examining trajectories of functional disability – a post-hoc analysis of Zavegepant
Jessica Cirillo (New York, NY, US)
P200
ePoster
Clinical characteristics and outcomes of status migrainosus in a tertiary hospital
Gonçalo Cabral (Lisboa, PT)
P201
ePoster
Combined effects of cannabidiol and Δ9-tetrahydrocannabinol alleviate migraine-like sensitivity without motor impairment in FHM1 and WT mice
Georgii Krivoshein (Leiden, NL)
P202
ePoster
Long-term effectiveness of eptinezumab in patients with migraine and 2-4 prior preventive treatment failures who self-reported psychiatric comorbidities at screening
Patricia Pozo-Rosich (Barcelona, ES)
P203
ePoster
Contemporary prospective understanding of migraine real-world evidence (CAPTURE): baseline migraine treatment patterns
Laurent Delahaye (Toronto, CA)
P204
ePoster
Efficacy of fremanezumab treatment for migraine prevention in patients with migraine and major depressive disorder: results from the open-label extension of the UNITE study
Piero Barbanti (Rome, IT)
P205
ePoster
White matter hyperintensities in a Portuguese cohort of migraine patients: prevalence, characterization and clinical correlations
Stefanie Moreira (Braga, PT)
P206
ePoster
Risk factors for migraine onset – a systematic review and three-level meta-analysis
Maria Terhart (Berlin, DE)
P207
ePoster
Long-term outcomes (over 24 months) of anti-CGRP therapy in migraine – a real-world single-center study
Mariana Henriques (Lisboa, PT)
P208
ePoster
Electrophysiological disparities in trigeminal ganglion neurons induced by serotonin depletion: Implications for migraine in rats model
Sirikorn Vongseenin (Bangkok, TH)
P209
ePoster
Comparison of brain structural MRI before and after 6-months of preventive treatment with anti-CGRP monoclonal antibodies and onabotulinumtoxinA in people with migraine
Joana Rosell-Mirmi (Barcelona, ES)
P210
ePoster
Is migraine a severity predictor in CADASIL patients? Early results from CADA-Migraine study
Danilo Antonio Montisano (Milano, IT)
P211
ePoster
Analysis of serum alpha-CGRP levels in different disorders and its meaning regarding the specificity of increased concentrations of the peptide for chronic migraine
Gabriel Gárate (Santander, ES)
P212
ePoster
Impact of Atogepant on long-term response rates and migraine-specific quality of life in migraine prevention: interim analysis of a phase 3, multicenter, open-label, 156-week extension study
Peter J. Goadsby (London, GB; Los Angeles, CA, US)
Jonathan H. Smith (North Chicago, IL, US)
P213
ePoster
Psychiatric comorbidities in migraine patients and the influence of monoclonal antibody therapy against CGRP – preliminary results
Catarina Fernandes (Coimbra, PT)
P214
ePoster
Psychiatric and sleep disorders in migraine patients: common comorbidities
Joana Cancela (Coimbra, PT)
P215
ePoster
Cortical spreading depolarization-evoked cortical inflammation correlates with activation of meningeal macrophages
Ya Han Chang (Taipei, TW)
P216
ePoster
Preliminary results utilizing the Ussing Chamber to investigate meningeal properties
Mette Nyholm Jensen (Glostrup, DK; Copenhagen, DK)
P217
ePoster
Reliability and validity of Turkish version of migraine specific quality of life v2.1 questionnaire
Aynur Özge (Mersin, TR)
P218
ePoster
Influence of precipitants on the characteristics of Chronic migraine study. Study in a series of 1584 patient
Álvaro Sierra Mencia (Valladolid, ES)
P219
ePoster
MIGARGILE tool: How can it help for patient with migraine recruitment in randomized clinical trial?
María de los Ángeles Sosa (Barcelona, ES)
P220
ePoster
Structural connectivity changes in migraine involving the cerebellum
Raquel Gil-Gouveia (Lisboa, PT)
P221
ePoster
Effectiveness of laser acupuncture for anxiety and depression among patients with chronic migraine – propensity score matching study
Ching-Chun Chung (Taichung, TW)
P222
ePoster
Telemedicine suitability prediction in migraine care – a machine learning approach
David Petrosian (Vilnius, LT)
P223
ePoster
Phenotyping interictal migraine patients according to clinical and psychophysical characteristics
Matteo Castaldo (Aalborg, DK)
P224
ePoster
Cabergoline as a preventive migraine treatment – a randomized clinical pilot trial
Astrid Hjelholt (Aarhus, DK; Aalborg, DK)
P225
ePoster
The RELEASE umbrella study: An international, non-interventional, prospective cohort study assessing the effectiveness of Eptinezumab in patients initiating preventive treatment for migraine
Gustavo Luna (Valby, DK)
P226
ePoster
Effect of testosterone therapy on migraine in a patient with congenital bilateral anorchia
Stefanie Moreira (Braga, PT)
P227
ePoster
Migraine is associated with a significantly increased risk for breast cancer – data of more than 1.5 million women
Gabriele Susanne Merki Feld (Zürich, CH)
P228
ePoster
Perspectives and expectations of chronic migraine patients receiving and not receiving OnabotulinumtoxinA on physiotherapy and rehabilitation treatment
Dilara Onan (Yozgat, TR)
P229
ePoster
Utilization of healthcare resources and sick leave in a large cohort of migraine patients – a real-world data analysis
Matanya Tirosh (Herzliya, IL)
Danna Davidovici (Herzliya, IL)
P230
ePoster
Cervical stabilization exercise training via telerehabilitation in individuals with migraine – a randomized controlled trial
Elif Sena Dusgun (Istanbul, TR)
P231
ePoster
Possibilities of mindfulness-based cognitive therapy in the treatment of chronic headaches
Dora Perczel-Forintos (Budapest, HU)
P314
ePoster
Contralateral cranial autonomic symptoms in migraine patients, in Azerbaijani population
Ilaha Azizova (Baku, AZ)
P315
ePoster
A hidden burden – the impact of medication collection in hospital pharmacies in multiple sclerosis and migraine patients
Mariana Henriques (Lisboa, PT)
P316
ePoster
Low-level 810nm laser acupuncture for patients with chronic migraine – a follow-up phase of randomized controlled trial
Yuan Chen Liu (Taichung, TW)
P317
ePoster
Relationships between migraine and interoception
Siobhan Jones (Newcastle upon Tyne, GB)
P318
ePoster
Attentional network deficits in migraine patients: neural indicators and implications
Yu Xin Chen (Beijing, CN)
P319
ePoster
Melatonin for migraine prevention – a meta-analysis of efficacy and safety
Sandesh Warudkar (Ahmedabad, IN)
P320
ePoster
Transcranial Doppler in migraine
Hasmik Vekilyan (Yerevan, AM)
P321
ePoster
Migraine and cognitive dysfunction: a narrative review
Catarina Fernandes (Coimbra, PT)
P322
ePoster
Occipital nerve block as a safe and effective treatment for the management of refractory migraine in a pregnant woman
Aikaterini Foska (Athens, GR)
P323
ePoster
Assessment of Cutaneous Allodynia and its relation to Proinflammatory blood markers in migraine
Mona Nada (Cairo, EG)
P324
ePoster
Understanding the anti-migraine effect of MG25, a novel curcumin derivative through
invitro
and
invivo
perspectives
Kanthiah Deepika (Secunderabad, IN)
P325
ePoster
Serum melatonin levels and migraine headache: results from a cross-sectional study in Iran
Mansoureh Togha (Tehran, IR)
v1.20.0
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy